Keith Duffy, MD
MOHS-Micrographic Surgery · Salt Lake City, UTNPI 1770779050
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.2%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 3 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 56.2% of the total. Reporting peaked in 2020 at $1,980 and has fallen 98.6% since, to $27 in 2024.
Across 5 payments — averaging $916.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$3K
- LEO Pharma AS$2K
- Novartis$27
Across 9 payments — averaging $212.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$2K
What the payments were for
- Consulting fees$1,98043%
- Speaking & faculty fees$2,57456%
- Food & beverage$271%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 3 | $2,574 |
| LEO Pharma AS | 1 | $1,980 |
| Novartis | 1 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LIBTAYO$2,574
How this compares
Too few mohs-micrographic surgery providers in Utahto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Imiquimod | 15 | $289 |
| Cephalexin | 13 | $115 |
Paid to pharmacies, not to this prescriber.
Other mohs-micrographic surgery in Salt Lake City
- Breton YatesSalt Lake City$5K
- Jennifer StrunckSalt Lake City$697
- Jessica DoniganSalt Lake City$340
- Michael EyreSpanish Fork$9K
- Chad PetersonSpanish Fork$6K
- Jared HeatonBountiful$3K
- Sealtiel TinajeroRichfield$3K
- Cory MaughanProvidence$2K
- Emily PowellOgden$1K
- Jake FaganProvo$759
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.